Click on the icon to enter
MENARINI BENELUX N.V./S.A. also owes its dynamic growth to the innovative quality of its medicines.
Pharmacovigilance:
The reporting of suspected adverse reactions after authorization of a medicinal product is important. It allows continuous monitoring of the benefit/risk ratio of the medicinal product.
If you want to report an adverse reaction you presented while using one of our medicines:
- Please send us a message , mentioning : •the name of the medicine, •the adverse reaction(s), •if you agree to be contacted to provide us further information. We will then contact you as soon as possible.
- You can also directly report the adverse reactions to the authorities via their network – choose your country:
|
In Belgium:
Federal Agency for Medicines and Health Products, Vigilance Division, Boîte Postale 97, B-1000 BRUSSELS, Madou –
Website:
https://www.famhp.be/en/side_effect
- e-mail: adr@fagg.be
|
In Luxembourg :
via the Centre Régional de Pharmacovigilance de Nancy, Bâtiment de Biologie Moléculaire et de Biopathologie (BBB), CHRU de Nancy – Hôpitaux de Brabois, Rue de Morvan, 54 511 Vandoeuvre les Nancy Cedex, tél : (+33) 3 83 65 60 85/87, e-mail : crpv@chru-nancy.fr
Or
la Direction de la Santé, Division de la Pharmacie et des Médicaments, 20, rue de Bitbourg, L-1273 Luxembourg-Hamm, tél. (+352) 2478 5592, e-mail : pharmacovigilance@ms.etat.lu.
Lien pour le formulaire :
www.guichet.lu/pharmacovigilance
|
In the Netherlands:
report directly via the Dutch Side Effects Center Lareb:
Website: www.lareb.nl
|